Skip to main content

Veracyte

Veracyte Inc is an American genomic diagnostics company providing novel diagnostic tests for cancer and thyroid disorders. The company develops and commercializes genomic tests including Afirma, Decipher, Percepta, and Envisia, utilizing machine learning and RNA sequencing. Revenue is generated from diagnostic testing services provided through its CLIA-certified laboratory alongside diagnostic product kit sales to pathology centers. Core end markets serve endocrinologists, urologists, pulmonologists, oncologists, and clinical health networks in the United States and international markets. Veracyte occupies a leading position in genomic cancer diagnostics, guiding treatment decisions in early-stage cancer management. The company is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market.

7 of the funds FundTelligence covers report a position in Veracyte.

Legal name
Veracyte Inc
Sector
Health Care
Country
United States
Funds holding it
7
Exposure themes
Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics

Funds holding Veracyte

Loading...